Targacept

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Targacept ( TRGT) is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. This stock closed up 1.3% to $5.28 in Tuesday's trading session.

Tuesday's Range: $5.07-$5.30
52-Week Range: $3.85-$5.77
Thursday's Volume: 305,000
Three-Month Average Volume: 219,969

>>4 Big Stocks on Traders' Radars

From a technical perspective, TRGT bounced modestly higher here right above its 50-day moving average of $4.98 with above-average volume. This move is quickly pushing shares of TRGT within range of triggering a near-term breakout trade. That trade will hit if TRGT manages to take out some near-term overhead resistance at $5.33 with high volume.

Traders should now look for long-biased trades in TRGT as long as it's trending above its 50-day at $4.98 or above its 200-day at $4.63 and then once it sustains a move or close above $5.33 with volume that hits near or above 219,969 shares. If that breakout triggers soon, then TRGT will set up to re-test or possibly take out its next major overhead resistance levels at its 52-week high of $5.77 to $6. Any high-volume move above $6 will then give TRGT a chance to re-fill some of its previous gap down zone from March of 2012 that started near $7.70.

To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

If you liked this article you might like

Athersys (ATHX) Strong On High Relative Volume Today

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

Here’s Why Athersys (ATHX) Stock is Jumping Today

Athersys (ATHX) Stock Advances on Healios Licensing Agreement

5 Breakout Stocks Under $10 Set to Soar